S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Latest freight railroad layoffs and Wall Street pressure renew concerns about safety and service
Critical asset just had biggest fall on record (Ad)
One year after buying a failed bank, New York Community Bancorp is struggling
Dell, NetApp rise; Ginkgo Bioworks, New York Community Bancorp fall, Friday, 3/1/2024
Critical asset just had biggest fall on record (Ad)
How major US stock indexes fared Friday, 3/1/2024
China pledges to increase opportunities for foreign companies as it seeks to boost its economy
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Brazil's economy grows 2.9% in Lula's 1st year, beating expectations
A US appeals court ruling could allow mine development on Oak Flat, land sacred to Apaches
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Latest freight railroad layoffs and Wall Street pressure renew concerns about safety and service
Critical asset just had biggest fall on record (Ad)
One year after buying a failed bank, New York Community Bancorp is struggling
Dell, NetApp rise; Ginkgo Bioworks, New York Community Bancorp fall, Friday, 3/1/2024
Critical asset just had biggest fall on record (Ad)
How major US stock indexes fared Friday, 3/1/2024
China pledges to increase opportunities for foreign companies as it seeks to boost its economy
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Brazil's economy grows 2.9% in Lula's 1st year, beating expectations
A US appeals court ruling could allow mine development on Oak Flat, land sacred to Apaches
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Latest freight railroad layoffs and Wall Street pressure renew concerns about safety and service
Critical asset just had biggest fall on record (Ad)
One year after buying a failed bank, New York Community Bancorp is struggling
Dell, NetApp rise; Ginkgo Bioworks, New York Community Bancorp fall, Friday, 3/1/2024
Critical asset just had biggest fall on record (Ad)
How major US stock indexes fared Friday, 3/1/2024
China pledges to increase opportunities for foreign companies as it seeks to boost its economy
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Brazil's economy grows 2.9% in Lula's 1st year, beating expectations
A US appeals court ruling could allow mine development on Oak Flat, land sacred to Apaches
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Latest freight railroad layoffs and Wall Street pressure renew concerns about safety and service
Critical asset just had biggest fall on record (Ad)
One year after buying a failed bank, New York Community Bancorp is struggling
Dell, NetApp rise; Ginkgo Bioworks, New York Community Bancorp fall, Friday, 3/1/2024
Critical asset just had biggest fall on record (Ad)
How major US stock indexes fared Friday, 3/1/2024
China pledges to increase opportunities for foreign companies as it seeks to boost its economy
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Brazil's economy grows 2.9% in Lula's 1st year, beating expectations
A US appeals court ruling could allow mine development on Oak Flat, land sacred to Apaches
NASDAQ:GALT

Galectin Therapeutics (GALT) Stock Price, News & Analysis

$1.93
-0.03 (-1.53%)
(As of 03/1/2024 ET)
Today's Range
$1.90
$2.02
50-Day Range
$1.60
$1.96
52-Week Range
$1.28
$2.47
Volume
123,603 shs
Average Volume
54,168 shs
Market Capitalization
$119.37 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$11.00

Galectin Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
469.9% Upside
$11.00 Price Target
Short Interest
Bearish
4.93% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.83mentions of Galectin Therapeutics in the last 14 days
Based on 3 Articles This Week
Insider Trading
Acquiring Shares
$895 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($0.74) to ($0.66) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.37 out of 5 stars

Medical Sector

570th out of 952 stocks

Pharmaceutical Preparations Industry

265th out of 440 stocks


GALT stock logo

About Galectin Therapeutics Stock (NASDAQ:GALT)

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.

GALT Stock Price History

GALT Stock News Headlines

GALT Galectin Therapeutics Inc.
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Galectin Therapeutics GAAP EPS of -$0.24
Galectin Therapeutics: Q3 Earnings Insights
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Galectin Therapeutics Inc. (PHPN.F)
8-K: GALECTIN THERAPEUTICS INC
See More Headlines
Receive GALT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Galectin Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/15/2021
Today
3/02/2024
Next Earnings (Estimated)
4/04/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:GALT
Employees
12
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$11.00
High Stock Price Target
$11.00
Low Stock Price Target
$11.00
Potential Upside/Downside
+469.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-38,780,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
($0.58) per share

Miscellaneous

Free Float
29,255,000
Market Cap
$119.37 million
Optionable
Optionable
Beta
0.82
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

  • Mr. Joel Lewis (Age 54)
    President, CEO & Director
    Comp: $870.66k
  • Mr. Jack W. Callicutt CPA (Age 57)
    CFO, Treasurer & Corporate Secretary
    Comp: $492.62k
  • Dr. Pol F. Boudes M.D. (Age 67)
    Ph.D., Chief Medical Officer
    Comp: $720.64k
  • Robert Tritt
    General Counsel
  • Mr. Jeff Katstra
    Head of CMC & Pharmaceutical Development
  • Ms. Beth Knowles
    Executive Assistant & Officer Manager














GALT Stock Analysis - Frequently Asked Questions

Should I buy or sell Galectin Therapeutics stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Galectin Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" GALT shares.
View GALT analyst ratings
or view top-rated stocks.

What is Galectin Therapeutics' stock price target for 2024?

1 brokers have issued 1-year target prices for Galectin Therapeutics' stock. Their GALT share price targets range from $11.00 to $11.00. On average, they predict the company's share price to reach $11.00 in the next year. This suggests a possible upside of 469.9% from the stock's current price.
View analysts price targets for GALT
or view top-rated stocks among Wall Street analysts.

How have GALT shares performed in 2024?

Galectin Therapeutics' stock was trading at $1.66 at the beginning of the year. Since then, GALT shares have increased by 16.3% and is now trading at $1.93.
View the best growth stocks for 2024 here
.

When is Galectin Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, April 4th 2024.
View our GALT earnings forecast
.

How were Galectin Therapeutics' earnings last quarter?

Galectin Therapeutics Inc. (NASDAQ:GALT) posted its earnings results on Monday, November, 15th. The company reported ($0.14) earnings per share for the quarter, beating the consensus estimate of ($0.18) by $0.04.

What ETFs hold Galectin Therapeutics' stock?

ETFs with the largest weight of Galectin Therapeutics (NASDAQ:GALT) stock in their portfolio include Horizon Kinetics Medical ETF (MEDX),

What other stocks do shareholders of Galectin Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Galectin Therapeutics investors own include Sorrento Therapeutics (SRNE), Catalyst Pharmaceuticals (CPRX), Viking Therapeutics (VKTX), Exelixis (EXEL), Progenics Pharmaceuticals (PGNX), Rigel Pharmaceuticals (RIGL), TherapeuticsMD (TXMD), Novavax (NVAX), Verastem (VSTM) and Immunomedics (IMMU).

Who are Galectin Therapeutics' major shareholders?

Galectin Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Atria Wealth Solutions Inc. (0.40%), Cambridge Investment Research Advisors Inc. (0.20%), Cutter & CO Brokerage Inc. (0.19%), Solutions 4 Wealth Ltd (0.06%), Beacon Capital Management LLC (0.04%) and Retirement Guys Formula LLC (0.03%). Insiders that own company stock include Elissa J Schwartz, Fund LP 10X, Jack W Callicutt, Joel Lewis, Kary Eldred, Kevin D Freeman and Richard A Jr Zordani.
View institutional ownership trends
.

How do I buy shares of Galectin Therapeutics?

Shares of GALT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:GALT) was last updated on 3/2/2024 by MarketBeat.com Staff